ASCO 2022 | EV-103: neoadjuvant enfortumab vedotin in cis-ineligible MIBC

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, discusses updated results from Cohort H of the EV-103 study (NCT03288545), evaluating the antitumour activity of neoadjuvant enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible. Observed pathological complete response rate after neoadjuvant enfortumab vedotin showed promising activity in cis-ineligible patients with muscle-invasive bladder cancer who have a high unmet need. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.